乌干达血吸虫病流行岛屿学龄儿童中强化吡喹酮给药对疫苗特异性应答的影响(POPVAC A):一项开放标签随机对照试验
在乌干达科梅群岛8所小学9-17岁学龄儿童中开展开放标签随机对照试验,比较强化与标准吡喹酮给药对疫苗应答的影响。强化组在首次接种前2周内接受3剂约40 mg/kg吡喹酮(间隔2周),此后每3个月一次;标准组在第8周主要终点后接受1剂约40 mg/kg。基线曼氏血吸虫阳性者中,强化组显著降低接种前感染强度,但降低第8周HPV-16特异性IgG应答,对其他主要结局无影响;全部参与者中强化组显著改善第8周BCG特异性IFNγ ELISpot应答。
要点
- 基线曼氏血吸虫阳性者中,强化吡喹酮显著降低接种前感染强度(中位30 CAA pg/mL vs 1317,p<0·001)。
- 强化吡喹酮降低第8周HPV-16特异性IgG应答(几何均值比0·71,95%CI 0·54-0·94,p=0·017)。
- 全部参与者中强化吡喹酮显著改善第8周BCG特异性IFNγ ELISpot应答(1·20,95%CI 1·01-1·43,p=0·038)。
核心结论
- 证据提示吡喹酮给药改善BCG特异性细胞应答,但不改善对其他疫苗的体液应答。
- 尽管观察性证据显示蠕虫损害疫苗应答,这些结果显示减少蠕虫负荷的即刻益处有限。
- 应研究长期蠕虫控制的效果。
研究设计与样本
- 开放标签随机对照试验,在乌干达科梅群岛8所小学9-17岁学龄儿童中比较强化与标准抗曼氏血吸虫干预。
- 采用计算机生成1:1随机化,区组大小为4、6、8和10。
- 2019年7月9日至8月14日入组478名参与者,每组239名;276名(58%)为男性,202名(42%)为女性。
- 主要分析人群为基线曼氏血吸虫感染者(强化组171名[72%],标准组164名[69%]),回顾性采用血浆循环阳极抗原(CAA)或粪便PCR确定。
- 安全性人群包括所有随机分配参与者;试验注册于ISRCTN Registry(ISRCTN60517191)并已完成。
主要发现
- 基线曼氏血吸虫阳性者中,强化组接种前感染强度中位30 CAA pg/mL(IQR 7-223)vs 标准组1317(IQR 243-8562),p<0·001。
- 强化组第8周HPV-16特异性IgG应答几何均值比0·71(95%CI 0·54-0·94),p=0·017,较标准组降低。
- 全部参与者中,强化组第8周BCG特异性IFNγ ELISpot应答1·20(95%CI 1·01-1·43),p=0·038,较标准组升高。
- 强化组报告吡喹酮已知不良反应更频繁;两组均无严重不良事件记录。
关键数值与推荐
- 强化组:首次接种(第0周)前2周内接受3剂吡喹酮(约40 mg/kg),间隔2周,此后每3个月一次。
- 标准组:第8周主要终点后接受1剂约40 mg/kg吡喹酮。
- 两组第0周接种BCG疫苗(Serum Institute of India, Pune, India);第4周接种黄热病疫苗(Sanofi Pasteur, Lyon, France)、口服伤寒疫苗(PaxVax, London, UK)和首剂人乳头瘤病毒(HPV)疫苗(Merck, Rahway, NJ, USA);第28周接种HPV加强针和破伤风-白喉疫苗(Serum Institute of India)。
- 主要结局为第8周疫苗应答(破伤风和白喉在第52周评估)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine responses differ between populations and are often impaired in rural and low-income settings. The reasons for this are not fully understood, but observational data suggest that the immunomodulating effects of parasitic helminths might contribute. We hypothesised that Schistosoma mansoni infection suppresses responses to unrelated vaccines, and that suppression could be reversed-at least in part-by intensive praziquantel administration. METHODS: We conducted an open-label, randomised controlled trial of intensive versus standard intervention against S mansoni among schoolchildren aged 9-17 years from eight primary schools in Koome islands, Uganda. Children were randomly allocated to either an intensive group or a standard group with a computer-generated 1:1 randomisation using permuted blocks sizes 4, 6, 8, and 10. Participants in the intensive group received three praziquantel doses (approximately 40 mg/kg) 2 weeks apart before first vaccination at week 0, and every 3 months thereafter. Participants in the standard group were given one dose of approximately 40 mg/kg praziquantel after the week 8 primary endpoint. Participants in both groups received the BCG vaccine (Serum Institute of India, Pune, India) at week 0; the yellow fever (Sanofi Pasteur, Lyon, France), oral typhoid (PaxVax, London, UK), and first human papillomavirus (HPV) vaccination (Merck, Rahway, NJ, USA) at week 4; and the HPV booster and tetanus-diphtheria vaccine (Serum Institute of India) at week 28. The primary outcome was vaccine response at week 8 (except for tetanus and diphtheria, which was assessed at week 52). The primary analysis population was participants who were infected with S mansoni at baseline, determined retrospectively using either plasma circulating anodic antigen (CAA) or stool PCR. The safety population comprised all randomly allocated participants. The trial was registered at the ISRCTN Registry (ISRCTN60517191) and is complete. FINDINGS: Between July 9 and Aug 14, 2019, we enrolled 478 participants, with 239 children per group. 276 (58%) participants were male and 202 (42%) participants were female. Among participants who were positive for S mansoni at baseline (171 [72%] in the intensive group and 164 [69%] in the standard group) intensive praziquantel administration significantly reduced pre-vaccination infection intensity (to median 30 CAA pg/mL [IQR 7-223] vs 1317 [243-8562], p<0·001) compared with standard treatment. Intensive praziquantel administration also reduced week 8 HPV-16-specific IgG response (geometric mean ratio 0·71 [95% CI 0·54-0·94], p=0·017), but had no effect on other primary outcomes. Among all participants (regardless of S mansoni status at baseline) intensive praziquantel administration significantly improved week 8 BCG-specific IFNγ ELISpot response (1·20 [1·01-1·43], p=0·038). Recognised adverse effects of praziquantel were reported more frequently in the intensive group. There were no recorded serious adverse events in either group. INTERPRETATION: We show evidence suggesting that praziquantel administration improves the BCG-specific cellular response, but not humoral responses to other vaccines. Despite observational evidence that helminths impair vaccine response, these results show minimal immediate benefits of reducing helminth burden. The effect of longer-term helminth control should be investigated. FUNDING: UK Medical Research Council. TRANSLATION: For the Luganda translation of the abstract see Supplementary Materials section.
引用
- Nkurunungi G, Nassuuna J, Natukunda A, et al. The effect of intensive praziquantel administration on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands (POPVAC A): an open-label, randomised controlled trial. Lancet Glob Health. 2024. PMID: 39424571. doi:10.1016/S2214-109X(24)00280-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。